Acceder

Publicaciones - Investigación en Pediatría

Cargando...
Alvarez-Gutierrez FJ, Blanco Aparicio M, Casas Maldonado F, Plaza V, Soto Campos G, Gonzalez-Barcala FJ, Almonacid C, Arismendi E, Cabrera C, Cabestre Garcia R, Carretero JA, Castilla Martinez M, Castillo Vizuete JA, Cisneros Serrano C, Diaz de Atauri AG, Diaz Perez D, Domingo Ribas C, Garcia Rivero JL, Lopez Neyra A, Martinez Moragon E, de Mir Messa I, Munoz Gall X, Padilla Galo A, Perpina Tordera M, Perez de Llano L, Sanchez Toril F, Sanz Santiago V, Valverde Molina J. [Consensus document for Severe Asthma. 2025 Update]. Open Respir Arch. 2025 Aug 31;7(4):100486. doi: 10.1016/j.opresp.2025.100486. eCollection 2025 Oct-Dec. Spanish. PubMed PMID: 41049458; PubMed Central PMCID: PMC12495165.
AÑO: 2025
Serrano-Belmonte I, Cascales-Perez FJ, Perez-Fernandez V, Martinez-Canovas A, Tudela-Mulero MR, Rosales-Leal JI. Effects of adding graphene fibers to polymethyl methacrylate on biocompatibility and surface characterization. J Prosthet Dent. 2025 Jan;133(1):281.e1-281.e8. doi: 10.1016/j.prosdent.2024.07.043. Epub 2024 Sep 4. PubMed PMID: 39232936.
AÑO: 2025; IF: 4.8
Miralles-Lopez JC, Cortes Collado JJ, Petryk Petryk Y, Bravo-Gutierrez FJ, Andujar-Espinosa R, Ramirez Hernandez M, Castilla-Martinez M, Diaz-Chantar C, Ibarra-Calabuig I, Valverde-Molina J, Perez-Fernandez V, Group RA. Real-life efficacy of Tezepelumab in patients with failure to other biologic drugs. Eur Ann Allergy Clin Immunol. 2025 Oct 10. doi: 10.23822/EurAnnACI.1764-1489.416. Online ahead of print. No abstract available. PubMed PMID: 41070810.
AÑO: 2025; IF: 2.3
Alvarez-Gutierrez FJ, Casas-Maldonado F, Valverde-Molina J. News From the Severe Asthma Consensus 2025 Review. Arch Bronconeumol. 2025 Nov 14:S0300-2896(25)00409-0. doi: 10.1016/j.arbres.2025.11.003. Online ahead of print. No abstract available. English, Spanish. PubMed PMID: 41314900.
AÑO: 2025; IF: 9.2
Gupta A, de Mir Messa I, Valverde-Molina J, Murray CS, Moral L, Torres Borrego J, Pike K, Diaz-Izquierdo A, Martinez-Canavate A, Nagakumar P, Cook J, Gupta L; CASAM Group. Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM). PLoS One. 2025 Dec 19;20(12):e0335399. doi: 10.1371/journal.pone.0335399. eCollection 2025. PubMed PMID: 41417800; PubMed Central PMCID: PMC12716689.
AÑO: 2025; IF: 2.6
< AnteriorSiguiente >

Instituto de Investigación Sanitaria Acreditado

ISCII